# Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.

> **NCT00417261** · PHASE1 · COMPLETED · sponsor: **Novartis** · enrollment: 65 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ATF936
- **DRUG:** AXT914

## Key facts

- **NCT ID:** NCT00417261
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** 2008-04
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2008-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00417261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00417261, "Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00417261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*